Objectives: Scedosporium infections are associated with high therapeutic failure rates. Combination therapy may be an alternative approach to improve outcome. The in vitro and in vivo efficacy of micafungin plus posaconazole or plus voriconazole was investigated herein.
Introduction
Scedosporium species cause a wide spectrum of infections in healthy and immunocompromised patients ranging from classical subcutaneous infections, like mycetoma, which spread via the lymphatic system, to disseminated infections with CNS involvement. 1 -3 The three major clinically relevant species within the genus Scedosporium are Scedosporium apiospermum, Scedosporium aurantiacum and Scedosporium boydii. 4 -6 While S. boydii and S. apiospermum are mainly reported from temperate climate zones, S. aurantiacum has its niche in arid areas. 6 Due to the slow growth on routine media (.14 days), and the absence of standardized diagnostics assays, their real incidence and clinical significance are likely to be underestimated. 2, 7 So far, S. apiospermum and S. boydii share highly similar in vitro antifungal susceptibility patterns. 8, 9 The majority of S. apiospermum and S. boydii isolates are resistant to amphotericin B, caspofungin, anidulafungin, isavuconazole and itraconazole. 8, 9 Among the azoles, voriconazole and posaconazole show the highest in vitro activity, while micafungin is the most active echinocandin. 9 Due to limited treatment options at hand and high rates of therapeutic failures (including voriconazole as first-line recommendation) observed (50% -70%), 7, 10 new strategies are desperately needed to improve patient outcome. A combination of a triazole and micafungin seems to be an attractive treatment regimen, as both drugs differ in their antifungal targets and subsequently in the mode of action. Such combination could act in a complementary manner and thereby improve efficacy, which has been demonstrated for other fungal pathogens. 11 -16 However, the usefulness of combination therapy for treating fungal infections is at present controversial; in most cases it is applied as salvage therapy in patients who are refractory to antifungal monotherapy. 17 -19 The aims of this study were: (i) to evaluate the efficacy of micafungin in combination with posaconazole or voriconazole against S. apiospermum and S. boydii infections in a well-established, immunocompromised murine model of systemic scedosporiosis; and (ii) to estimate whether the fractional inhibitory concentration index (FICI; in vitro characteristic measure for combination therapies) is a good parameter to predict the outcome of in vivo drug combinations. The current study represents the first in vivo study of an azole/echinocandin combination therapy against S. apiospermum complex infections.
Materials and methods

Strain set
A total of 43 Scedosporium strains (17 S. boydii and 26 S. apiospermum) were investigated (see Table 1 ) and identified to species level in a previous study using the amplified fragment length polymorphism method. 9 In vitro susceptibility testing Strains were cultured on potato dextrose agar for 10 days at 308C. To evaluate the in vitro activity of micafungin and posaconazole or voriconazole, a two-dimensional chequerboard method according to CLSI M38-A2 20 and Dannaoui et al. 21 was used; in addition, we applied the commercially available Etest w system (BioMérieux S.A, France). The MICs of azoles (posaconazole and voriconazole) and minimal effective concentrations (MECs) of micafungin were determined according to CLSI broth microdilution standards for filamentous fungi. 20 For micafungin/triazole combinations, the endpoint was based on the MEC of the echinocandins and the MIC-2 (defined as an 50% reduction in growth compared with the control) of the triazoles, as the suitability of this approach was shown previously by Calvo et al. 22 Using the Etest In a pilot study, Etest w and the chequerboard method were compared for their suitability (the criteria being operator-independent objectivity, reproducibility of results, number of unreadable or unclear results) using a randomly chosen collection of nine strains ( Figure S1 , available as Supplementary data at JAC Online). Strains and drug combinations were tested in triplicate and results were read by two independent investigators.
Murine model
To evaluate the in vivo efficacy of micafungin and voriconazole or posaconazole, two strains per species (Table S1 , available as Supplementary data at JAC Online) based on their FICI values were selected, and inocula were prepared as previously described by Calvo et al. 24 Four-week-old, male OF-1 mice (Charles River, Criffa SA, Barcelona, Spain) with a body weight between 28.0 and 30.0 g were used as model organisms. Animals were housed in standard boxes with corncob bedding and free access to food and water/grapefruit juice. Procedures were supervised and approved by Luis Loriente Sanz (ID 39671243) of the Veterinary and Animal Welfare Advisory Board of the Universitat Rovira i Virgili Animal Welfare and Ethics Committee (Reus, Spain). Animals were cared for in line with national guidance.
The mice were randomly chosen for the different treatment and control groups. Three days prior to infection (day 23), mice in the voriconazole group (applicable for mono-and combination therapy) received grapefruit juice instead of water. 25 At day 21, all mice were immunosuppressed via intraperitoneal administration of a single dose of 200 mg/kg of cyclophosphamide plus a single dose of 150 mg/kg of 5-fluorouracil given intravenously. 26 Animals were infected at day 0 with 5×10 3 conidia/mouse via lateral tail vein injection; treatment started at day +1 and was continued until day +11. Clinical formulations of micafungin (Mycamine w ), posaconazole (Noxafil w ) and voriconazole (Vfend w ) were used throughout. Each treatment group received micafungin at 10 mg/kg intraperitoneally once daily, 27 posaconazole at 20 mg/kg orally by gavage twice a day, 28 voriconazole at 40 mg/kg orally by gavage once daily, 10 micafungin plus posaconazole or micafungin plus voriconazole, or served as an untreated control. For survival studies, mice were checked once a day until day +30. Animals meeting the criteria for discomfort or survivors after the experiment were killed by CO 2 inhalation. The fungal load was determined on day +6 (day when the first mouse of the control group died) for comparison with the controls. Kidneys and brain were aseptically removed and approximately half of each organ was weighed, mechanically homogenized in 1 mL of 0.9% NaCl and serially 10-fold diluted. Dilutions were plated on potato dextrose agar and incubated at 308C for 7 days for cfu determination per gram of organ.
Statistical analyses
Mean survival time was estimated using the Kaplan -Meier method and compared among groups with the log rank test. Tissue load was analysed with the Mann-Whitney U-test using GraphPad Prism version 6. Due to the multiple groups for comparison, a P value ,0.016 was regarded as statically significant.
Results and discussion
For reasons of practicability and objectivity, chequerboard broth microdilution was the method of choice, as Etest w determination of MECs for micafungin was highly operator-dependent and difficult to read ( Figure S1 ). Data are given in Table S2 (available as Supplementary data at JAC Online). Also, Mukherjee et al. 29 report contradictory results between Etest w and the broth microdilution method when evaluating various drug combinations (including azole/echinocandin combinations) against a wide range of fungal pathogens.
For both combinations tested, voriconazole/micafungin and posaconazole/micafungin, the majority of strains showed no interactions (approx. 86% and 88%, respectively; Table S3 , available as Supplementary data at JAC Online). Synergistic or antagonistic effects were detected in only a few strains (Table 1) . So far, our in vitro results were in agreement with findings previously published by Cuenca-Estrella et al., 30 reporting 'no interaction' as the most frequently observed category. In general, combinatorial in vitro data are scarce for the S. apiospermum complex; only a few data on colistin/voriconazole, colistin/caspofungin, colistin/ amphotericin B, 31 micafungin/amphotericin B 32 and micafungin/ voriconazole 33 are available. Our study represents the first in vivo evaluation of micafungin plus voriconazole or posaconazole for members of the S. apiospermum complex. In general, all drugs applied (with the exception of Lackner et al. Micafungin/azole combinations against scedosporiosis 3029 JAC micafungin monotherapy) prolonged survival significantly when compared with controls (P,0.016) (Figure 1 ). In contrast, statistically significant differences in survival were lacking between combinations and triazole monotherapies applied. Furthermore, differences in in vivo outcome as predicted by FICI were not observed, even though FICI values ranged from 0.37 to 8.24 (synergism to strong antagonism) for S. boydii and 0.09 to 4.5 (synergism to no interaction) for S. apiospermum, respectively. In particular, strains showing in vitro antagonism or no interaction for micafungin/voriconazole or micafungin/posaconazole responded equally well in vivo to strains showing in vitro synergism. Efforts were made to standardize in vitro and in vivo methods for testing the antifungal activity of combinations, but solid agreement on the in vitro method of choice was not achieved. 29, 34 Mice infected with the strain CBS 117419 (S. boydii) had the highest mortality rates; only voriconazole monotherapy and voriconazole plus micafungin showed some activity. With respect to survival, voriconazole and its combination were the most efficient therapies for all infected groups independent of the species and the strain tested. The effectiveness of voriconazole against scedosporiosis as monotherapy was previously demonstrated in in vivo studies. 8, 28, 33, 35 Results of fungal tissue burdens are given in Figure 2 . In the treatment of S. apiospermum (FMR 13015), any combination significantly reduced the fungal load in all organs with respect to control and micafungin monotherapy, but not when compared with triazole monotherapy. For mice challenged with either of the S. boydii strains (FMR 12741 and FMR 13004), both combinations (voriconazole/micafungin and posaconazole/micafungin) significantly reduced tissue loads when compared with their respective monotherapies (P, 0.016). These findings were independent of the FICIs. Even though in vitro results showed an antagonistic effect for S. boydii strain FMR 13004, there was no correlation between in vitro and in vivo results. In summary, no signs of antagonism were observed in vivo either in prolongation of survival or in reduction of fungal load. Thus, the current data suggest an absence of harm or negative interaction when an azole is combined with micafungin. Rojas et al. 17 confirmed that the combination of caspofungin/voriconazole was well tolerated and that antagonism was not observed in patients. Moreover, they found caspofungin plus voriconazole to be favourable for the treatment of patients suffering from invasive fungal infections, including invasive scedosporiosis. 17 Other authors reported favourable outcomes or at least the use of such a combination for the treatment of invasive scedosporiosis. 17 -19 In our study, in mice infected with either of the two S. boydii strains, posaconazole followed by voriconazole was the most effective drug treatment with respect to fungal burden. However, differences between posaconazole and voriconazole treatment were not statistically significant.
Our study displays some limitations as we tested only a limited number of strains for in vivo outcome and did not perform investigations on drug -drug interactions in terms of toxicities in mice; nevertheless, our results clearly show that FICI values are not predictive for in vivo outcome and that treatment response is rather strain-than species-dependent. The discrepancy between in vitro and in vivo results, as well as the lack of species dependency on outcome, complicates any treatment prognosis. Drug efficacy experiments showed voriconazole, posaconazole and their combinations with micafungin to be the most effective treatment Lackner et al.
strategies for invasive scedosporiosis. In a few cases, Rojas et al.
17
showed patients failing with treatment with voriconazole or posaconazole to benefit from combination therapy.
Conclusions
Voriconazole and posaconazole monotherapies were equally efficient as the combination therapies with micafungin. Therefore, combination therapy cannot be regarded as beneficial for the management of patients suffering from invasive scedosporiosis. Micafungin as monotherapy failed to be efficient. FICI-predicted antagonistic effects for posaconazole/micafungin and voriconazole/micafungin remained unconfirmed in vivo. FICI is not a reliable measure for predicting the in vivo azole/echinocandin outcome in the case of invasive scedosporiosis.
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